SCHEMBL5136624

SCHEMBL5136624

CCCCC(c1cnc(-c2ccccc2)n1CCCC)N(CCCC)Cc1ccc(O)cc1

nearest known ligand 0.40

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
TSHR P16473 1/20 0.40
LTB4R2 Q9NPC1 2/20 0.37
HSD11B1 P28845 2/20 0.35
C5AR1 P21730 1/20 0.34
BCHE P06276 2/20 0.32
NR1H3 Q13133 1/20 0.32
PDE4B Q07343 2/20 0.32
ALDH1A1 P00352 2/20 0.32
KDM4E B2RXH2 2/20 0.32
HSD17B10 Q99714 2/20 0.32
HPGD P15428 1/20 0.31
NPC1 O15118 1/20 0.31
MAPT P10636 1/20 0.31
STAT3 P40763 1/20 0.31
RAB9A P51151 1/20 0.31
ATM Q13315 1/20 0.31
SMN1; SMN2 Q16637 1/20 0.31
CXCR3 P49682 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5134566 0.94 TSHR (0.41) TSHRLTB4R2HSD11B1C5AR1BCHE
SCHEMBL5136148 0.90 OPRK1 (0.40) TSHRC5AR1BCHENR1H3PDE4B
SCHEMBL5136829 0.89 TSHR (0.39) TSHRHSD11B1C5AR1NR1H3PDE4B
SCHEMBL5071417 0.89 TSHR (0.39) TSHRLTB4R2HSD11B1BCHEPDE4B
SCHEMBL650145 0.86 LPAR1 (0.40) TSHRALDH1A1KDM4EMAPTSMN1; SMN2
SCHEMBL5136862 0.86 C5AR1 (0.36) TSHRLTB4R2HSD11B1C5AR1ALDH1A1
SCHEMBL5136261 0.86 TSHR (0.35) TSHRLTB4R2C5AR1CXCR3
SCHEMBL5135184 0.86 TSHR (0.38) TSHRHSD11B1C5AR1NR1H3PDE4B
SCHEMBL4763850 0.86 TSHR (0.35) TSHRLTB4R2C5AR1CXCR3
SCHEMBL5134818 0.85 TSHR (0.39) TSHRC5AR1PDE4B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1490044-A4 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORP (US) 2008-04-16 EP disclosed
EP-1490044-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2004-12-29 EP disclosed
WO-2003084524-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2003-10-16 WO disclosed